XM
AIM

XTX Markets’s AIM ImmunoTech AIM Stock Holding History

XTX Markets’s Portfolio AIM Stock Details AIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$20K Sell
110
-9
-8% -$1.8K 0.04% 192
2020
Q3 		$26K Buy
+119
New +$29.7K 0.12% 97

Other funds holding AIM

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
SWM
SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return

XTX Markets's AIM Position: Q4 2020 in Review

XTX Markets reduced its AIM ImmunoTech (AIM) stake by 7.6% in Q4 2020, selling an estimated $1.8K and leaving 110 shares worth $20K. The position accounts for 0.04% of the portfolio, ranked #192.

XTX Markets first reported a position in AIM in Q3 2020 and has held it in 2 quarters since. The position peaked at $26K in Q3 2020. 33 funds tracked by Wall St. Rank hold AIM as of Q4 2020.

  • XTX Markets held 110 shares of AIM ImmunoTech worth $20K as of Q4 2020.
  • XTX Markets sold 9 AIM ImmunoTech shares in Q4 2020, an estimated $1.8K.
  • AIM ImmunoTech made up 0.04% of XTX Markets's portfolio in Q4 2020, its #192 holding.
  • XTX Markets first reported a position in AIM ImmunoTech in Q3 2020 and has held it in 2 quarters since.
  • XTX Markets's AIM ImmunoTech position peaked at $26K in Q3 2020.
  • 33 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q4 2020.

Based on XTX Markets's 13F filing for Q4 2020, filed 25 Jan 2021.